Astrazeneca

FromAstraZeneca ([email protected])
Sent withMailchimp
Subject (95)Koselugo approved in the EU for plexiform neurofibromas in adults with neurofibromatosis type 1
Preheader (95)Koselugo approved in the EU for plexiform neurofibromas in adults with neurofibromatosis type 1
Typography
Arial
Colors
Text Analysis
Body Words119
Subject Words14
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images6
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px708 px
X-Spam Score-0.1
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeEvening

Koselugo approved in the EU for plexiform neurofibromas in adults with neurofibromatosis type 1

Koselugo approved in the EU for plexiform neurofibromas in adults with neurofibromatosis type 1
Koselugo approved in the EU for plexiform neurofibromas in adults with neurofibromatosis type 1